✦ LIBER ✦

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumors

✍ Scribed by Pronk, L.C.; Schrijvers, D.; Schellens, J.H.M.; de Bruijn, E.A.; Planting, A.S.Th.; Locci-Tonelli, D.; Groult, V.; Verweij, J.; van Oosterom, A.T.

Book ID: 118575302
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 64 KB
Volume: 18
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(97)83970-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

961 Phase I study of docetaxel and ifosf

961 Phase I study of docetaxel and ifosfamide in patients with advanced solid tumors

✍ L. Pronk; D. Shrijvers; D. Locci-Tonelli; J. Verweij; A.T. Van Oosterom 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 161 KB

Phase I study on docetaxel and ifosfamid

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours

✍ Pronk, LC; Schrijvers, D; Schellens, JHM; de Bruijn, EA; Planting, ASTh; Locci-T 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 1014 KB

Phase I study of weekly CPT-11 (irinotec

Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors

✍ Font, A; Sanchez, J.M; Rosell, R; Taron, M; Martinez, E; Guillot, M; Manzano, J. 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 102 KB

Phase I study of docetaxel and topotecan

Phase I study of docetaxel and topotecan in patients with solid tumors

✍ Katherine H. Tkaczuk; William C. Zamboni; Nancy S. Tait; Barry R. Meisenberg; L. 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 103 KB

Phase I dose escalation study of docetax

Phase I dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors

✍ Gregory A. Masters; Bruce E. Brockstein; Sridhar Mani; Mark J. Ratain 📂 Article 📅 2003 🏛 Springer US 🌐 English ⚖ 69 KB

Phase I evaluation of docetaxel and topo

Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors

✍ Anne S. Tsao; Dong M. Shin; J. Lynn Palmer; Jin S. Lee; Bonnie S. Glisson 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

## Abstract ## BACKGROUND The authors administered a combination of docetaxel and topotecan with granulocyte–colony‐stimulating factor (G‐CSF) support in a Phase I study to define the maximum tolerated dose (MTD) of this regimen. ## METHODS Patients with advanced‐stage solid tumors were eligible